StockNote
HDP
Ha Tinh Pharmaceutical Joint Stock Company (HDP), formerly known as Ha Tinh Pharmaceutical State Company, was established in 1960. The company operates mainly in the field of manufacturing, trading and import and export of pharmaceuticals and medical supplies. HDP has officially operated under the model of a joint stock company since 2004. The company currently manages and operates 02 medical treatment factories meeting the Good Manufacturing Practice (GMP-WHO) standards in Ha Tinh with more than 150 drug names registered for circulation. Typical products of HDP include HT White Flower Wood, Perfume Finisher, HT3 Neural Mixture, Rhomantic Gel, and Goltakmin. HDP has been traded on the UPCOM market since March 2017.
HDP currently has a market capitalization of roughly VND 258 billion, placing it in the small-cap group on the Vietnamese stock market. Its current P/E of 12,4x is 10% above its own 6-year average (11,3x), suggesting the stock is trading richer than its historical norm. P/B stands at 2,2x, 55% above its multi-year average of 1,4x. Return on equity (ROE) is at 15,2%, up from 12,3% the year before. Its debt-to-equity ratio of 0,6x is moderate, reflecting a balanced capital structure. In 2025, revenue fell 0% year-on-year while after-tax profit grew 27%.
This note is generated automatically from the stock's real financial data, for reference only — not investment advice.
Revenue & Profit
Unit: VND billion. Growth (%) vs. previous period.
Not enough data for this period.
Market Cap
Unit: VND billion. Year-end values; current year uses latest session.
Debt / Equity
Unit: x. Financial debt over shareholders' equity.
Data aggregated from cafef.vn and VNDirect, for reference only, not investment advice.